01—Abstract
Summary
Summary of the 10-Q filed October 29, 2024. Cited figures are marked; the original filing is the authoritative source.
Leidos Holdings, Inc. reported third-quarter 2024 revenues of $4.19 billiona, up from $3.92 billion in the prior-year quarter, a 6.9% increase.
Operating income was $516 millionb, a 12.3% operating margin, compared with an operating loss of $336 million in the year-earlier quarter, which included a $599 million goodwill impairment and an $88 million asset impairment. Net income attributable to Leidos common stockholders was $364 million, or $2.68 diluted EPS, versus a loss of $399 million, or $(2.91) per diluted share, a year earlier. For the nine months, revenues rose 7.3% to $12.30 billion, operating income was $1.41 billion (11.4% operating margin), and diluted EPS was $7.13.
The company reported net bookings of $8.1 billionc in the quarter and $15.8 billion for the nine months, compared with $7.9 billion and $13.8 billion a year earlier. Total backlog was $40.56 billion at September 27, 2024, up from $38.04 billion, and remaining performance obligations were $16 billion. Health & Civil was the strongest segment, with a 23.4% operating margin in the quarter.
Cash and cash equivalents increased to $1.19 billiond from $0.78 billion at fiscal year-end 2023, and nine-month operating cash flow was $1.09 billion, compared with $0.86 billion a year earlier. Quarterly operating cash flow of $656 million was lower than the $795 million reported in the prior-year quarter. The filing also discloses an ongoing internal investigation into international operations, which the company has self-reported to the Department of Justice and the SEC, along with a separate Department of Justice Antitrust Division criminal investigation.
The company states it cannot predict the timing, outcome, or possible impact of these matters. Shareholder returns included quarterly dividends of $0.38 per share and open-market share repurchases of $450 million over the nine months.
02—Key points
Key Highlights
- Third-quarter revenues were $4.19 billion, up 6.9% from $3.92 billion, and operating income was $516 million versus an operating loss of $336 million a year earlier, which included a $599 million goodwill impairment.
- Diluted EPS was $2.68 for the quarter and $7.13 for the nine months, compared with $(2.91) and $(0.22) in the prior-year periods.
- Net bookings were $8.1 billion in the quarter and $15.8 billion year to date, and total backlog reached $40.56 billion at September 27, 2024, versus $38.04 billion a year earlier.
- Health & Civil posted a 23.4% operating margin in the quarter on revenue growth of 16.1%, and Commercial & International returned to positive operating income of $41 million.
- Cash and cash equivalents rose to $1.19 billion, and nine-month operating cash flow increased to $1.09 billion from $0.86 billion, though third-quarter operating cash flow declined to $656 million from $795 million.
- The company repurchased $450 million of its common stock on the open market during the nine months and paid quarterly dividends of $0.38 per share.
- The company is subject to an internal FCPA-related investigation self-reported to the DOJ and SEC, and a DOJ Antitrust Division criminal investigation; the filing states it cannot estimate potential fines or liabilities.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in Q3 FY2025, Leidos Holdings kept $0.09.
- Revenue$4.17B100.0%
- Cost of revenue−$3.43B82.2%
- Gross profit$741.0M17.8%
- Operating costs−$225.0M5.4%
- Operating income$516.0M12.4%
- Interest, other & tax−$152.0M3.6%
- Net income$364.0M8.7%
04—Financials
Financial Highlights
Figures from 10-QQ3 FY2025filed October 29, 2024Financial Statements
Q3 FY2025 against Q3 FY2024
| Line item | Q3 FY2025Q3 FY2024 | Change |
|---|---|---|
| Revenue | $4.17B$3.90B | +7.0% |
| Cost of Revenue | $3.43B$3.33B | +2.8% |
| Gross Profit | $741.00M$563.00M | +31.6% |
| SG&A Expenses | $247.00M$239.00M | +3.3% |
| Operating Income | $516.00M-$336.00M | +253.6% |
| Net Income | $364.00M-$399.00M | +191.2% |
| EPS (Basic) | $2.72$-2.91 | +193.5% |
| EPS (Diluted) | $2.68$-2.91 | +192.1% |
| Shares Outstanding (Basic) | 134.00M137.00M | −2.2% |
| Shares Outstanding (Diluted) | 136.00M137.00M | −0.7% |
05—Questions
Frequently Asked Questions
How did Leidos perform in the third quarter of 2024 compared with the prior year?
Revenues increased 6.9% to $4.19 billion from $3.92 billion. Operating income was $516 million, or a 12.3% operating margin, compared with an operating loss of $336 million in the third quarter of 2023, which included goodwill and asset impairment charges. Net income attributable to Leidos common stockholders was $364 million, or $2.68 per diluted share, compared with a loss of $399 million, or $(2.91) per diluted share.
What is the company's contract backlog and bookings outlook?
Net bookings were an estimated $8.1 billion in the third quarter and $15.8 billion for the nine months, compared with $7.9 billion and $13.8 billion in the prior-year periods. Total backlog was $40.56 billion at September 27, 2024, including $9.09 billion funded and $31.47 billion unfunded. Remaining performance obligations were $16 billion, with approximately 66% expected to be recognized over the next 12 months and 82% over the next 24 months.
How dependent is Leidos on U.S. government spending?
The company generated approximately 87% of total revenues from U.S. government contracts in both the three and nine months ended September 27, 2024. The filing notes a continuing resolution funding the government through December 20, 2024, and states that failure to pass appropriations or another continuing resolution by that date would result in a partial or complete federal government shutdown.
What legal and regulatory matters could affect the company?
The company is conducting an internal investigation, overseen by an independent Board committee, into international operations conduct that may have violated the U.S. Foreign Corrupt Practices Act, and has self-reported it to the DOJ and SEC. It also received a Federal Grand Jury subpoena in August 2022 in a criminal investigation by the DOJ Antitrust Division related to three procurements. The company states it cannot anticipate the timing, outcome, or impact of these matters and cannot determine whether it will incur fines or penalties.
How is the company returning capital to shareholders and managing its debt?
Dividends of $0.38 per share were paid each quarter, totaling $155 million over the nine months. Open-market repurchases totaled $200 million in the third quarter and $450 million for the nine months. Total long-term debt was $4.67 billion at September 27, 2024, with $592 million classified as current, and the company reported no commercial paper outstanding and was in compliance with all debt covenants.
06—Continue